Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 692.58 USD -1.52% Market Closed
Market Cap: 72.8B USD

Regeneron Pharmaceuticals Inc
Other Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Regeneron Pharmaceuticals Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Liabilities
$545.6m
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other Current Liabilities
$12.3B
CAGR 3-Years
139%
CAGR 5-Years
67%
CAGR 10-Years
37%
Amgen Inc
NASDAQ:AMGN
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Other Current Liabilities
$239.5m
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
26%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Liabilities
$441.5m
CAGR 3-Years
27%
CAGR 5-Years
18%
CAGR 10-Years
34%
No Stocks Found

Regeneron Pharmaceuticals Inc
Glance View

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

REGN Intrinsic Value
748.93 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Regeneron Pharmaceuticals Inc's Other Current Liabilities?
Other Current Liabilities
545.6m USD

Based on the financial report for Sep 30, 2025, Regeneron Pharmaceuticals Inc's Other Current Liabilities amounts to 545.6m USD.

What is Regeneron Pharmaceuticals Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
13%

Over the last year, the Other Current Liabilities growth was -13%.

Back to Top